奥古斯丁治疗公司完成超额认购的7800万欧元A轮融资-动脉网

Augustine Therapeutics raises oversubscribed EUR 78 million Series A financing round

D-Pharm 等信源发布 2025-03-31 11:46



可切换为仅中文







Augustine Therapeutics NV, a biotechnology company focused on developing new therapies for neuromuscular, neurodegenerative and cardio-metabolic diseases through the inhibition of the cytosolic Histone DeACetylase 6 (HDAC6) enzyme, announced it has successfully completed its

奥古斯丁治疗公司（Augustine Therapeutics NV），一家专注于通过抑制细胞质组蛋白去乙酰化酶6（HDAC6）酶来开发神经肌肉、神经退行性和心代谢疾病新疗法的生物技术公司，宣布已成功完成其…

Series A financing

A轮融资

round raising a total of EUR 77.7 million (USD 84.8 million). The oversubscribed financing was co-led by Novo Holdings and Jeito Capital, supported by existing investors Asabys Partners, who led an initial EUR 17.5 million closing in 2024, Eli Lilly and Company, AdBio partners, V-Bio Ventures, PMV, VIB, Gemma Frisius Fund, the US-based Charcot-Marie-Tooth (CMT) Research Foundation and Newton Biocapital..

一轮融资共筹集了7770万欧元（8480万美元）。这笔超额认购的融资由诺和控股和Jeito Capital共同领投，现有投资者Asabys Partners支持，后者在2024年领投了最初的1750万欧元融资，其他投资者包括礼来公司、AdBio合作伙伴、V-Bio Ventures、PMV、VIB、Gemma Frisius基金、美国的Charcot-Marie-Tooth（CMT）研究基金会和Newton Biocapital。

HDAC6 is involved in neurodegeneration and tissue aging-related cellular processes, and pharmacologic inhibition of HDAC6 is a promising approach in a number of diseases. Augustine Therapeutics have designed a unique next-generation approach to selectively inhibit HDAC6 while preserving its beneficial non-catalytic functions.

HDAC6 参与神经退行性病变和组织衰老相关的细胞过程，药理学抑制 HDAC6 是多种疾病治疗的有前景的方法。奥古斯丁治疗公司设计了一种独特的下一代方法，可以选择性抑制 HDAC6，同时保留其有益的非催化功能。

This novel non-hydroxamate, non-hydrazine producing approach seeks to avoid the limitations of previous HDAC6i and has significant potential in CMT, the most common hereditary disorder of the peripheral nervous system, affecting approximately three million people worldwide. With additional independent and differentiated programs focused on brain-penetrant and peripheral-restricted molecules, Augustine’s pipeline of HDAC6 inhibitors has further potential in multiple diseases, including neurodegenerative and cardio-metabolic disorders..

这种新型的非羟肟酸、非肼生产方法旨在避免以往HDAC6抑制剂的局限性，在CMT（最常见的遗传性周围神经系统疾病，影响全球约三百万人）中具有显著潜力。通过额外独立且差异化开发的专注于能穿透大脑和限制在周围神经系统的分子项目，Augustine公司的HDAC6抑制剂管线在包括神经退行性疾病和心脑代谢障碍等多种疾病中展现出更大的潜力。

The Company’s scientific foundation originates from the ground-breaking research of Prof. Ludo Van Den Bosch from the VIB-KU Leuven Center for Brain and Disease Research, who identified HDAC6 inhibition as a promising approach for the treatment of CMT and other neuropathies. Augustine was initially formed and seed-funded by V-Bio Ventures, AdBio Partners, VIB, PMV, and Gemma Frisius Fund.

公司的科学基础源自VIB-KU Leuven大脑与疾病研究中心的Ludo Van Den Bosch教授的开创性研究，他发现HDAC6抑制是治疗CMT及其他神经病变的一种有前景的方法。Augustine最初由V-Bio Ventures、AdBio Partners、VIB、PMV和Gemma Frisius基金创立并提供了种子资金。

The Company recently appointed experienced biopharma leader Gerhard Koenig, PhD, who had served as Executive Chairman since June 2024, to lead the Company as CEO in January 2025..

公司最近任命了经验丰富的生物制药领域领导者 Gerhard Koenig 博士为首席执行官，他自2024年6月起担任执行主席，并将于2025年1月起领导公司。

Protein aggregates save cells during aging

蛋白质聚集体在衰老过程中拯救细胞

Max Planck Scientists identify new role of protein aggregates in neurodegeneration

马克斯·普朗克科学家发现蛋白质聚集在神经退行性疾病中的新作用

Read news

读新闻

The proceeds will be used to advance Augustine’s lead candidate, AGT-100216, through a Phase I/II proof-of-concept clinical trial in CMT. Beyond AGT-100216, Augustine has two other programs in discovery targeting peripherally-restricted and blood-brain barrier-penetrant HDAC6i for undisclosed neurodegenerative and cardio-metabolic indications..

这笔资金将用于推动 Augustine 的主要候选药物 AGT-100216 进入 CMT 的 I/II 期概念验证临床试验。除了 AGT-100216，Augustine 还有另外两个处于探索阶段的项目，分别针对外周限制性和血脑屏障穿透性的 HDAC6 抑制剂，用于未公开的神经退行性疾病和心代谢适应症。

Gerhard Koenig, PhD, CEO of Augustine said: “This significant financing is a testament to the innovative medicinal chemistry that Augustine was founded on, which acts via a unique mechanism of action. The therapeutic potential of HDAC6 is widely recognized in our industry, but previous drug approaches have been sub-optimal, particularly for chronic diseases.

Gerhard Koenig，哲学博士，Augustine的首席执行官表示：“这项重要的融资证明了Augustine创立时所基于的创新药物化学，其通过独特的作用机制发挥作用。HDAC6的治疗潜力在我们行业内得到广泛认可，但以前的药物方法并不理想，特别是对于慢性疾病。”

At Augustine, we believe we have solved these challenges with a novel non-hydroxamate, non-hydrazide producing chemotype which is highly selective and avoids the typical limitations of prior chemotypes, unlocking HDAC6 inhibition as a therapeutic approach. We now look forward to rapidly advancing our lead candidate into clinical trials for the treatment of CMT, while broadening the potential for our candidates to change treatment paradigms for neurological and cardio-metabolic diseases. I would like to thank our new and existing investors for their unwavering support as we continue to advance into clinical development.”.

在奥古斯丁，我们相信我们已经通过一种新颖的非羟肟酸、非肼化物生成化学型解决了这些挑战，这种化学型具有高度选择性，并避免了以往化学型的典型局限性，从而开启了HDAC6抑制作为一种治疗方法的可能性。我们现在期待快速推进我们的先导候选药物进入临床试验，以治疗CMT，同时扩大我们的候选药物改变神经和心脑代谢疾病治疗模式的潜力。我要感谢我们新的和现有的投资者，感谢他们在我们继续向临床开发迈进过程中的不懈支持。"

Emmanuelle Coutanceau, PhD, Partner, Seed Investments, Novo Holdings, commented: “Our mapping of the HDAC6i landscape has made us confident that Augustine’s innovative and rigorous approach to medicinal chemistry has yielded molecules with potential to be best-in-class. HDAC6 inhibition shows great promise in many indications, and we are enthused to start our collaboration with Augustine’s top-tier management team.

诺和控股种子投资合伙人埃曼努埃尔·库唐索博士评论道：“我们对HDAC6i领域的分析使我们相信，奥古斯丁在药物化学方面的创新与严谨方法已经产出了具有成为同类最佳潜力的分子。HDAC6抑制在许多适应症中展现出巨大的前景，我们非常高兴能与奥古斯丁的一流管理团队开始合作。”

Additionally, Augustine will be expanding its activities in Denmark, accessing a unique ecosystem and pool of talent which will support the exploration of HDAC6i in cardio-metabolic diseases.”.

此外，奥古斯丁公司还将扩大其在丹麦的业务活动，接触独特的生态系统和人才库，这将有助于对HDAC6i在心脑代谢疾病中的探索。"

Mehdi Ainouche, PharmD, Senior Principal, at Jeito Capital, said: “This investment illustrates the potential of Augustine to bring exciting innovation in therapeutic areas where patients have limited or no treatment options. We are delighted to co-lead this financing to realize Augustine’s potential, which stands out for both the quality of its research and the expertise of Gerhard and his team.

Jeito Capital的高级负责人、药学博士Mehdi Ainouche表示：“这项投资展示了Augustine在患者治疗选择有限或无治疗选择的领域带来令人兴奋的创新潜力。我们很高兴能够共同领导此次融资，以实现Augustine的潜力，其研究质量和Gerhard及其团队的专业知识都脱颖而出。”

We look forward to our future collaboration, which shares a common ambition: to accelerate clinical development in order to bring these innovations to patients.”.

我们期待未来的合作，双方都有着共同的雄心：加速临床开发，将这些创新成果带给患者。

Emmanuelle Coutanceau, PhD, Partner at Seed Investments, Novo Holdings, and Mehdi Ainouche, PharmD, Senior Principal at Jeito Capital have joined Augustine Therapeutics’ Board of Directors. Annette Clancy, Operational Investor at Jeito Capital, and Marie Schroeder, PhD, Vice President at Seed Investments, Novo Holdings will join as Board Observers..

Emmanuelle Coutanceau博士，诺和控股旗下Seed Investments的合伙人，以及Mehdi Ainouche药学博士，Jeito Capital的高级主管，已加入Augustine Therapeutics的董事会。Annette Clancy，Jeito Capital的操作投资者，以及Marie Schroeder博士，诺和控股旗下Seed Investments的副总裁，将作为董事会观察员加入。

https://www.bionity.com/en/news/1185912/augustine-therapeutics-raises-oversubscribed-eur-78-million-series-a-financing-round.html

AstronauTx closes £48 million Series A financing to create new treatments for Alzheimer's disease

AstronauTx 完成 4800 万英镑 A 轮融资，用于开发阿尔茨海默病新疗法

Biotech start-up company developing new treatments for neurodegenerative conditions based on amplifying the brain's own physiological protective mechanisms

生物技术初创公司，基于放大大脑自身的生理保护机制，开发神经退行性疾病的新型治疗方法。

Read news

读新闻